flecainide has been researched along with Drop Attack in 21 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study sought to compare the differences between procainamide and flecainide to stress the His-Purkinje system during electrophysiological study (EPS) in patients with syncope and bundle branch block (BBB)." | 7.91 | Flecainide Versus Procainamide in Electrophysiological Study in Patients With Syncope and Wide QRS Duration. ( Ferreira-Gonzalez, I; Francisco-Pasqual, J; García-Dorado, D; Martin-Sanchez, G; Moya-Mitjans, A; Oristrell, G; Perez-Rodon, J; Rivas-Gandara, N; Roca-Luque, I; Rodríguez-García, J; Santos-Ortega, A, 2019) |
| "In patients with false-negative responses to the provocative testing with flecainide, cardiac syncope predicts SCA, allowing a more extensive and individualized evaluation." | 7.88 | Role of syncope in predicting adverse outcomes in patients with suspected Brugada syndrome undergoing standardized flecainide testing. ( Avanzas, P; Calvo, D; Coto, E; García, D; Gómez, J; González-Vasserot, M; María de la Hera, J; Morís, C; Pablo Flórez, J; Pérez, D; Reguero, J; Rubín, J; Valverde, I, 2018) |
| "The flecainide test is widely used in Brugada syndrome." | 7.72 | Flecainide test in Brugada syndrome: a reproducible but risky tool. ( Ceriotti, C; Galimberti, P; Gasparini, M; Mantica, M; Napolitano, C; Priori, SG; Simonini, S, 2003) |
| " We describe the case of a 62-year-old male with latent Brugada syndrome in whom the intravenous infusion of flecainide for paroxysmal atrial fibrillation caused ECG abnormalities similar to those of an acute septal myocardial infarction." | 7.72 | [Infusion of flecainide in a patient with atrial fibrillation and latent Brugada's syndrome has determined modifications of the electrocardiogram similar to those of a septal myocardial infarct]. ( Carotenuto, F; Cirillo, R; D'Errico, L; di Palma, F; Fontana, D; Granato, L; Pagano, V; Sestri, C; Vitiello, N, 2003) |
| " This study assessed in 1,330 patients followed up for 292 +/- 393 days the predictive value for cardiovascular safety of a system by which patients were classified according to ventricular arrhythmias on entry, presence or absence of organic heart disease and drug dose for flecainide acetate." | 7.67 | Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide. ( Anderson, JL; Gentzkow, GD; Morganroth, J, 1986) |
| "This study sought to compare the differences between procainamide and flecainide to stress the His-Purkinje system during electrophysiological study (EPS) in patients with syncope and bundle branch block (BBB)." | 3.91 | Flecainide Versus Procainamide in Electrophysiological Study in Patients With Syncope and Wide QRS Duration. ( Ferreira-Gonzalez, I; Francisco-Pasqual, J; García-Dorado, D; Martin-Sanchez, G; Moya-Mitjans, A; Oristrell, G; Perez-Rodon, J; Rivas-Gandara, N; Roca-Luque, I; Rodríguez-García, J; Santos-Ortega, A, 2019) |
| "In patients with false-negative responses to the provocative testing with flecainide, cardiac syncope predicts SCA, allowing a more extensive and individualized evaluation." | 3.88 | Role of syncope in predicting adverse outcomes in patients with suspected Brugada syndrome undergoing standardized flecainide testing. ( Avanzas, P; Calvo, D; Coto, E; García, D; Gómez, J; González-Vasserot, M; María de la Hera, J; Morís, C; Pablo Flórez, J; Pérez, D; Reguero, J; Rubín, J; Valverde, I, 2018) |
| "The flecainide test is widely used in Brugada syndrome." | 3.72 | Flecainide test in Brugada syndrome: a reproducible but risky tool. ( Ceriotti, C; Galimberti, P; Gasparini, M; Mantica, M; Napolitano, C; Priori, SG; Simonini, S, 2003) |
| " We describe the case of a 62-year-old male with latent Brugada syndrome in whom the intravenous infusion of flecainide for paroxysmal atrial fibrillation caused ECG abnormalities similar to those of an acute septal myocardial infarction." | 3.72 | [Infusion of flecainide in a patient with atrial fibrillation and latent Brugada's syndrome has determined modifications of the electrocardiogram similar to those of a septal myocardial infarct]. ( Carotenuto, F; Cirillo, R; D'Errico, L; di Palma, F; Fontana, D; Granato, L; Pagano, V; Sestri, C; Vitiello, N, 2003) |
| " This study assessed in 1,330 patients followed up for 292 +/- 393 days the predictive value for cardiovascular safety of a system by which patients were classified according to ventricular arrhythmias on entry, presence or absence of organic heart disease and drug dose for flecainide acetate." | 3.67 | Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide. ( Anderson, JL; Gentzkow, GD; Morganroth, J, 1986) |
| "This multicenter study suggests that oral flecainide therapy is an effective and safe means of suppressing VAs in patients with ATS with KCNJ2 mutations, though the U-wave amplitude remained unchanged by flecainide." | 2.80 | Efficacy and safety of flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations. ( Aiba, T; Anzai, T; Hayashi, H; Horie, M; Ishibashi, K; Ishihara, M; Kamakura, S; Kimura, H; Kusano, K; Miyamoto, K; Miyamoto, Y; Nakajima, I; Noda, T; Ogawa, H; Ohno, S; Okamura, H; Shimizu, W; Tanioka, Y; Tsuboi, I; Tsuchiya, T; Yasuda, S; Yasuoka, C; Yoshida, Y, 2015) |
| "The short QT syndrome is characterized by familial sudden death, short refractory periods, and inducible ventricular fibrillation." | 2.71 | Short QT Syndrome: a familial cause of sudden death. ( Bianchi, F; Borggrefe, M; Gaita, F; Giustetto, C; Grossi, S; Riccardi, R; Richiardi, E; Schimpf, R; Wolpert, C, 2003) |
| "Catecholaminergic polymorphic ventricular tachycardia was diagnosed with the aid of an implantable loop recorder." | 1.39 | A de novo novel cardiac ryanodine mutation (Ser4155Tyr) associated with catecholaminergic polymorphic ventricular tachycardia. ( Anastasakis, A; Kotsaka, X; Luria, D; Mantziari, L; Paraskevaidis, S; Styliadis, IH; Vassilikos, V, 2013) |
| "Syncope was abolished after successful radiofrequency catheter ablation of the AFL." | 1.31 | Syncope in patients with atrial flutter during treatment with class Ic antiarrhythmic drugs. ( Azegami, K; Hiejima, K; Hirao, K; Horikawa, T; Kawabata, M; Motokawa, K; Suzuki, F; Suzuki, K, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (14.29) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Cheung, CC | 1 |
| Scheinman, M | 1 |
| Lee, BK | 1 |
| Luna-López, R | 1 |
| Datino, T | 1 |
| Espinosa, MÁ | 1 |
| Fernández-Avilés, F | 1 |
| Arenal, Á | 1 |
| Pablo Flórez, J | 1 |
| García, D | 1 |
| Valverde, I | 1 |
| Rubín, J | 1 |
| Pérez, D | 1 |
| González-Vasserot, M | 1 |
| Reguero, J | 1 |
| María de la Hera, J | 1 |
| Avanzas, P | 1 |
| Gómez, J | 1 |
| Coto, E | 1 |
| Morís, C | 1 |
| Calvo, D | 1 |
| El-Battrawy, I | 1 |
| Borggrefe, M | 2 |
| Lang, S | 1 |
| Zhou, X | 1 |
| Akin, I | 1 |
| Roca-Luque, I | 1 |
| Francisco-Pasqual, J | 1 |
| Oristrell, G | 1 |
| Rodríguez-García, J | 1 |
| Santos-Ortega, A | 1 |
| Martin-Sanchez, G | 1 |
| Rivas-Gandara, N | 1 |
| Perez-Rodon, J | 1 |
| Ferreira-Gonzalez, I | 1 |
| García-Dorado, D | 1 |
| Moya-Mitjans, A | 1 |
| Lokhandwala, Y | 1 |
| Kumar, B | 1 |
| Sato, A | 1 |
| Takano, T | 1 |
| Chinushi, M | 1 |
| Minamino, T | 1 |
| Mantziari, L | 1 |
| Vassilikos, V | 1 |
| Anastasakis, A | 1 |
| Kotsaka, X | 1 |
| Paraskevaidis, S | 1 |
| Styliadis, IH | 1 |
| Luria, D | 1 |
| Miyamoto, K | 1 |
| Aiba, T | 1 |
| Kimura, H | 1 |
| Hayashi, H | 2 |
| Ohno, S | 1 |
| Yasuoka, C | 1 |
| Tanioka, Y | 1 |
| Tsuchiya, T | 1 |
| Yoshida, Y | 1 |
| Tsuboi, I | 1 |
| Nakajima, I | 1 |
| Ishibashi, K | 1 |
| Okamura, H | 1 |
| Noda, T | 1 |
| Ishihara, M | 1 |
| Anzai, T | 1 |
| Yasuda, S | 1 |
| Miyamoto, Y | 1 |
| Kamakura, S | 1 |
| Kusano, K | 1 |
| Ogawa, H | 1 |
| Horie, M | 1 |
| Shimizu, W | 1 |
| Beinart, R | 1 |
| Michailidis, A | 1 |
| Gurevitz, OT | 1 |
| Glikson, M | 1 |
| Gasparini, M | 1 |
| Priori, SG | 1 |
| Mantica, M | 1 |
| Napolitano, C | 1 |
| Galimberti, P | 1 |
| Ceriotti, C | 1 |
| Simonini, S | 1 |
| Vitiello, N | 1 |
| Cirillo, R | 1 |
| Fontana, D | 1 |
| Granato, L | 1 |
| Sestri, C | 1 |
| Pagano, V | 1 |
| D'Errico, L | 1 |
| Carotenuto, F | 1 |
| di Palma, F | 1 |
| Gaita, F | 1 |
| Giustetto, C | 1 |
| Bianchi, F | 1 |
| Wolpert, C | 1 |
| Schimpf, R | 1 |
| Riccardi, R | 1 |
| Grossi, S | 1 |
| Richiardi, E | 1 |
| Haghjoo, M | 1 |
| Arya, A | 1 |
| Emkanjoo, Z | 1 |
| Sadr-Ameli, MA | 1 |
| Füessl, HS | 1 |
| Greenberg, HM | 1 |
| Dwyer, EM | 1 |
| Hochman, JS | 1 |
| Steinberg, JS | 1 |
| Echt, DS | 1 |
| Peters, RW | 1 |
| Itoh, E | 1 |
| Suzuki, K | 2 |
| Tanabe, Y | 1 |
| Kawabata, M | 1 |
| Hirao, K | 1 |
| Horikawa, T | 1 |
| Motokawa, K | 1 |
| Suzuki, F | 1 |
| Azegami, K | 1 |
| Hiejima, K | 1 |
| Borgeat, A | 1 |
| Grbic, M | 1 |
| Morganroth, J | 1 |
| Anderson, JL | 1 |
| Gentzkow, GD | 1 |
| Wehr, M | 1 |
| Noll, B | 1 |
| Krappe, J | 1 |
3 trials available for flecainide and Drop Attack
| Article | Year |
|---|---|
Efficacy and safety of flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations.
Topics: Administration, Oral; Adolescent; Adult; Andersen Syndrome; Anti-Arrhythmia Agents; Electrocardiogra | 2015 |
Short QT Syndrome: a familial cause of sudden death.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Complexes, Premature; Ch | 2003 |
Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I.
Topics: Angina Pectoris; Anti-Arrhythmia Agents; Databases, Factual; Death, Sudden, Cardiac; Drug Interactio | 1995 |
18 other studies available for flecainide and Drop Attack
| Article | Year |
|---|---|
A peculiar case of palpitations and syncope.
Topics: Andersen Syndrome; Arrhythmias, Cardiac; Flecainide; Humans; Mutation; Syncope | 2022 |
Permanent atrioventricular block after flecainide testing.
Topics: Aged; Atrioventricular Block; Brugada Syndrome; Electrocardiography; Female; Flecainide; Humans; Pac | 2020 |
Role of syncope in predicting adverse outcomes in patients with suspected Brugada syndrome undergoing standardized flecainide testing.
Topics: Adult; Anti-Arrhythmia Agents; Brugada Syndrome; Electrocardiography; False Negative Reactions; Fema | 2018 |
Sodium channel blockers in Brugada syndrome.
Topics: Ajmaline; Brugada Syndrome; Flecainide; Humans; Sodium Channel Blockers; Syncope | 2018 |
Flecainide Versus Procainamide in Electrophysiological Study in Patients With Syncope and Wide QRS Duration.
Topics: Aged; Aged, 80 and over; Bundle-Branch Block; Electrocardiography; Electrophysiologic Techniques, Ca | 2019 |
Flecainide to Unmask Infranodal Disease: A Better Sieve?
Topics: Bundle-Branch Block; Flecainide; Humans; Procainamide; Syncope | 2019 |
Usefulness of the intravenous flecainide challenge test before oral flecainide treatment in a patient with Andersen-Tawil syndrome.
Topics: Administration, Intravenous; Administration, Oral; Adult; Andersen Syndrome; Anti-Arrhythmia Agents; | 2019 |
A de novo novel cardiac ryanodine mutation (Ser4155Tyr) associated with catecholaminergic polymorphic ventricular tachycardia.
Topics: Adolescent; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Flecainide; Follow-Up Studi | 2013 |
Is flecainide dangerous in long QT-3 patients?
Topics: Anti-Arrhythmia Agents; Brugada Syndrome; Electrocardiography; Female; Flecainide; Humans; Long QT S | 2009 |
Flecainide test in Brugada syndrome: a reproducible but risky tool.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Bundle-Branch Block; Death, Sudden, Cardiac; Electrocardi | 2003 |
[Infusion of flecainide in a patient with atrial fibrillation and latent Brugada's syndrome has determined modifications of the electrocardiogram similar to those of a septal myocardial infarct].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Death, Sudden, Cardiac; Echocardiography; Electrocardio | 2003 |
Clinical and electrophysiologic profile of Brugada syndrome in Iranian patients.
Topics: Adult; Anti-Arrhythmia Agents; Bundle-Branch Block; Defibrillators, Implantable; Electric Stimulatio | 2005 |
[Reason for worry: syncope in the morning].
Topics: Anti-Arrhythmia Agents; Circadian Rhythm; Death, Sudden, Cardiac; Diagnosis, Differential; Electroca | 2005 |
A case of vasospastic angina presenting Brugada-type ECG abnormalities.
Topics: Acetylcholine; Aged; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cardiovascular Agents; Chest | 1999 |
Syncope in patients with atrial flutter during treatment with class Ic antiarrhythmic drugs.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Flutter; Catheter Ablation; Electrocardiography; Electrophysio | 2001 |
[Syncope in a 16-year-old young man during a football match].
Topics: Adolescent; Atrial Fibrillation; Flecainide; Humans; Male; Syncope; Wolff-Parkinson-White Syndrome | 1986 |
Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide.
Topics: Arrhythmias, Cardiac; Death, Sudden; Drug Administration Schedule; Flecainide; Heart Failure; Humans | 1986 |
Flecainide-induced aggravation of ventricular arrhythmias.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Female; Flecainide; Humans | 1985 |